Table 1

Comparison of baseline clinical demographics of test and control groups

Control Group

Test Group

P

Categories

(N = 18)

(N = 18)


Clinical assessment at entry

Age (Years)

62.8 ± 11.4

59.7 ± 14.9

NS

RA duration (Months)

88.1 ± 76.2

114.5 ± 92.6

NS

DAS28-ESR

5.64 ± 0.86

5.64 ± 1.37

NS

TJC

12.3 ± 6.1

15.9 ± 11.7

NS

SJC

12.6 ± 6.2

13.9 ± 7.8

NS

ESR (mm/hr)

46.7 ± 27.0

48.4 ± 32.9

NS

CRP (mg/dl)

2.5 ± 2.4

2.5 ± 2.8

NS

RF (IU/ml)

143 ± 102

213 ± 292

NS


Medication

PSL (mg/day)

2.72 ± 2.29

2.64 ± 2.94

NS

PSL (No.)

13

11

NS§

DMARDs (No.)

16

13

NS§

NSAIDs (No.)

14

11

NS§


Ochi's Classification

LES

3 (17%)

4 (22%)

NS§

MES

12 (66%)

10 (56%)

NS§

MUD

3 (17%)

4 (22%)

NS§


Complications and risk factor

Complication (No.)

9

9

NS§

Drug resistance (No.)

7

5

NS§

Drug allergy (No.)

2

4

NS§


Gastrointestinal Disorders

Constipation (No.)

12

12

NS§

Diarrhea (No.)

3

2

NS§

None (No.)

3

4

NS§


Data is shown as the mean ± standard deviation.

TJC: tender joint count, SJC: swollen joint count, RF: rheumatoid factor, PSL: Prednisolone, LES: least erosive subset, MES: more erosive subset, MUD: mutilating disease, NS: Not significant.

†: Determined by Mann Whitney U-test. §: Determined by Chi square test.

Katayama et al. Nutrition Journal 2011 10:2   doi:10.1186/1475-2891-10-2

Open Data